Unknown

Dataset Information

0

Effects of Metreleptin in Pediatric Patients With Lipodystrophy.


ABSTRACT: Lipodystrophy syndromes are rare disorders of deficient adipose tissue. Metreleptin, a human analog of leptin, improved metabolic abnormalities in mixed cohorts of children and adults with lipodystrophy and low leptin.Determine effects of metreleptin on diabetes, hyperlipidemia, nonalcoholic fatty liver disease (NAFLD), growth, and puberty in pediatric patients with lipodystrophy and low leptin.Prospective, single-arm, open-label studies with continuous enrollment since 2000.National Institutes of Health, Bethesda, Maryland.Fifty-three patients aged 6 months to <18 years with lipodystrophy, leptin level <8 ng/mL (male patients) or <12 ng/mL (female patients), and ?1 metabolic abnormality (diabetes, insulin resistance, or hypertriglyceridemia).Subcutaneous metreleptin injections (0.04 to 0.19 mg/kg/d).Change in A1c, lipid, and transaminase levels after a mean ± standard deviation (SD) of 12 ± 0.2 months and 61 ± 39 months. Changes in liver histology, growth, and pubertal development throughout treatment.After 12 months, the A1c level (mean ± SD) decreased from 8.3% ± 2.4% to 6.5% ± 1.8%, and median triglyceride level decreased from 374 mg/dL [geometric mean (25th,75th percentile), 190, 1065] to 189 mg/dL (112, 334; P < 0.0001), despite decreased glucose- and lipid-lowering medications. The median [geometric mean (25th,75th percentile)] alanine aminotransferase level decreased from 73 U/L (45, 126) to 41 U/L (25, 59; P = 0.001), and that of aspartate aminotransferase decreased from 51 U/L (29, 90) to 26 U/L (18, 42; P = 0.0002). These improvements were maintained over long-term treatment. In 17 patients who underwent paired biopsies, the NAFLD activity score (mean ± SD) decreased from 4.5 ± 2.0 to 3.4 ± 2.0 after 3.3 ± 3.2 years of metreleptin therapy (P = 0.03). There were no clinically significant changes in growth or puberty.Metreleptin lowered A1c and triglyceride levels, and improved biomarkers of NAFLD in pediatric patients with lipodystrophy. These improvements are likely to reduce the lifetime burden of disease.

SUBMITTER: Brown RJ 

PROVIDER: S-EPMC5443330 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4422900 | BioStudies
2019-01-01 | S-EPMC6563798 | BioStudies
2011-01-01 | S-EPMC3498767 | BioStudies
2017-01-01 | S-EPMC5433252 | BioStudies
2014-01-01 | S-EPMC4121033 | BioStudies
2019-01-01 | S-EPMC6676079 | BioStudies
2012-01-01 | S-EPMC3319219 | BioStudies
2018-01-01 | S-EPMC6063484 | BioStudies
2016-01-01 | S-EPMC4875885 | BioStudies
2019-01-01 | S-EPMC6688455 | BioStudies